000			05451nam a22003255i 4500
999			_c403034 _d403034
001			403034
003			ES-MaUEC
005			20240711100319.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			240229s2023 sz | o |||| 0|eng d
020			_a9783031386053
024	7		_a10.1007/978-3-031-38605-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .T6 _b2023 EB
245	0	0	_aPractical Management of Thyroid Cancer : _bA Multidisciplinary Approach _cedited by Ujjal K Mallick, Clive Harmer
250			_a3rd ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Pragmatism, Precision Oncology, International Partnership for Research and Quality-The New Paradigm for Thyroid Cancer -- Section I. Multidisciplinary Approach to Management of Thyroid Cancer -- 2. The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations -- 3. The 2015 American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Key Recommendations -- 4. Thyroid Cancer: One Doctor-Patient Partnership -The Newcastle Butterfly Model -- Section II. The Diagnosis of Thyroid Cancer -- 5. Molecular Diagnosis of Thyroid Nodules -- 6. Ultrasonography in Diagnosis and Management of Thyroid Cancer -Current International Recommendations -- Section III. Initial Thyroid Surgery -- 7. The 21st Century Endocrine Surgeon -- 8. Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer -- 9. Advances in Thyroid Surgery -- Section IV. Non surgical Management ofDifferentiated Thyroid Cancer -- 10. Risk Stratification and Current Management of Low Risk Thyroid Cancer -- 11. Management of Low risk Papillary Thyroid Carcinomo and Papillary Cancer and Microcarcinoma-the Japanese experience -- 12. Radioiodine Ablation - Current Status -- 13. Dosimetric Approaches - Current Concepts -- 14. External Radiation in Differentiated Thyroid Cancer in the era of IMRT and modern radiation planning techniques -- Section V. Follow up and Longterm Management of Differentiated Thyroid Cancer -- 15. Thyroglobulin -- 16. Management of Post-Operative Hypocalcemia -- 17. Radioiodine Refractory Thyroid Cancer -- Section VI. Medullary Thyroid Carcinoma -- 18. Medullary Thyroid Cancer :Surgical Management -- 19. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management -- 20. Familial Non-Medullary Thyroid Cancer -- Section VII. Thyroid Cancer in Children -- 21. Pediatric Differentiated Thyroid Carcinoma -- Section VIII. Aggressive ThyroidCancers -- 22. Anaplastic Thyroid Cancer -- 23. Palliative care -- Section IX. Future Developments and Directions for Research in Thyroid Cancer -- 24. Translational Research and Genomics Driven Trials in Thyroid Cancer -- 25. Thyroid Cancer Trials -- 26. The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer -- 27. Survivorship: The Role of the Clinical Psychologist and the Clinical Nurse Specialist in Thyroid Cancer Care.
520			_aWritten by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic. The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRK gene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed. The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well. This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
988			_aSpringer_Medicine_2023
650		7	_2embne _9173915 _aTiroides _xCáncer
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-38605-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b07/2024 _dz _eu _zSI